NRIX: Nurix Therapeutics Inc

NRIX新闻

• Investing 22:57 Nurix therapeutics (NRIX) CSO Hansen sells $51k in stock
• Investing 22:54 Nurix Therapeutics’ ring sells $46k in stock to cover tax obligations
• Investing 22:52 Nurix Therapeutics CFO van Houte sells $51,695 in shares
• Investing 14:58 Morgan Stanley lowers Nurix stock price target to $16 on higher spend
• TipRanks 17:03 Top 3 Trending Stocks, According to Analysts – 7/11/2025 - TipRanks.com
• Investing 12:12 Stifel maintains Buy rating on Nurix stock, sees $4.5B peak sales potential
• Investing 11:35 Nurix stock price target lowered to $26 by UBS on increased OpEx
• Investing 11:14 Goldman Sachs initiates Nurix stock with Buy rating, $182 price target
• Investing 11:04 Stifel reiterates Buy rating on Nurix stock, sees $4.5B peak sales potential
• Investing 00:02 Nurix earnings beat by $0.19, revenue topped estimates
• Investing 20:19 Nurix Therapeutics beats quarterly expectations on strong collaboration revenue
• Investing 11:45 Nurix stock maintains Buy rating at H.C. Wainwright on positive BTK degrader data
• Seeking Alpha 01:14 Tracking Baker Brothers Portfolio – Q1 2025 Update
• Investing 20:12 Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• Investing 13:58 Nurix stock price target reiterated at $30 by UBS on positive trial data
• Investing 13:52 Nurix stock price target raised to $28 from $27 at RBC Capital
• Investing 11:16 Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chroni
• Investing 11:13 Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congr
• Investing 11:18 Stifel analysts maintain Buy rating on Nurix stock after SNY deal
• Investing 14:31 UnitedHealth, Biontech lead Monday’s market cap stock movers
• Investing 12:36 Sanofi extends license option with Nurix’s STAT6 program
• Benzinga 12:12 Sanofi Expands Rare Immunology Portfolio With Blueprint Buyout - Nurix Therapeutics (NASDAQ:NRIX), Blueprint Medicines (NASDAQ:BPMC), Sanofi (NASDAQ:SNY)
• Investing 11:08 Nurix secures additional $15 million from Sanofi license deal
• Investing 11:24 Nurix Therapeutics to Participate in the Jefferies  Global Healthcare Conference